| Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. | |
| | |
MedLine Citation:
|
PMID: 22529202 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention? METHODS: The authors analyzed published studies from June 1999 to May 2009 using a structured review process to classify the evidence relative to the efficacy of various medications available in the United States for migraine prevention. RESULTS AND RECOMMENDATIONS: The author panel reviewed 284 abstracts, which ultimately yielded 29 Class I or Class II articles that are reviewed herein. Divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol, and timolol are effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity (Level A). Frovatriptan is effective for prevention of menstrual migraine (Level A). Lamotrigine is ineffective for migraine prevention (Level A). |
| | |
Authors:
|
S D Silberstein; S Holland; F Freitag; D W Dodick; C Argoff; E Ashman; |
Publication Detail:
|
Type: Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Neurology Volume: 78 ISSN: 1526-632X ISO Abbreviation: Neurology Publication Date: 2012 Apr |
Date Detail:
|
Created Date: 2012-04-24 Completed Date: 2012-07-20 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 0401060 Medline TA: Neurology Country: United States |
Other Details:
|
Languages: eng Pagination: 1337-45 Citation Subset: AIM; IM |
Affiliation:
|
Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
therapeutic use Angiotensin Receptor Antagonists / therapeutic use Angiotensin-Converting Enzyme Inhibitors / therapeutic use Anti-Inflammatory Agents, Non-Steroidal / therapeutic use Anticoagulants / therapeutic use Anticonvulsants / therapeutic use Antidepressive Agents / therapeutic use Benzimidazoles / therapeutic use Calcium Channel Blockers / therapeutic use Carbonic Anhydrase Inhibitors / therapeutic use Evidence-Based Medicine Humans Migraine Disorders / drug therapy*, prevention & control* Neuroprotective Agents / therapeutic use Parasympatholytics / therapeutic use Tetrazoles / therapeutic use Tryptamines / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Angiotensin Receptor Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Anti-Inflammatory Agents, Non-Steroidal; 0/Anticoagulants; 0/Anticonvulsants; 0/Antidepressive Agents; 0/Benzimidazoles; 0/Calcium Channel Blockers; 0/Carbonic Anhydrase Inhibitors; 0/Neuroprotective Agents; 0/Parasympatholytics; 0/Tetrazoles; 0/Tryptamines; 139481-59-7/candesartan |
| Comments/Corrections | |
Comment In:
|
Neurology. 2013 Feb 26;80(9):869-70
[PMID:
23439705
]
|
Erratum In:
|
Neurology. 2013 Feb 26;80(9):871 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Depth and duration of hypoglycaemia achieved during the insulin tolerance test.
Next Document: Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine pre...